Genprex Initiated at Buy by HC Wainwright & Co.
Genprex Initiated at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Initiates Coverage On Genprex With Buy Rating, Announces Price Target of $10
Genprex Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/25/2024 216.46% HC Wainwright & Co. → $10 Initiates Coverage On → Buy 01/30/2023 -5.06% Dawson James →
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AUSTIN, Texas — (March 22, 2024) — Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients wi
Genprex Shares Drop 12% on Latest Stock Offering to Get Proceeds of $5.8M
By Sabela Ojea Shares of Genprex on Wednesday dropped after the company agreed to sell common shares and warrants to purchase shares to raise net proceeds of about $5.8 million. In recent trading, s
JAGX and GNPX Among Health Care Movers
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersOntrak (NASDAQ:OTRK) shares increased by 97.6% to $0.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.3 million. Fusion Pharmaceuticals (NASDAQ:FUSN)
Express News | Genprex Shares Are Trading Lower After the Company Announced a $6.5 Million Registered Direct Offering
Genprex Shares Hit 52-Week Low After Direct Offering Prices
By Chris Wack Genprex shares were down 17% at $3.41, a 52-week low, after the company priced a registered direct offering expected to generate proceeds of $6.5 million. The stock is down 89% in the
Genprex Launches $6.5 Million Securities Offering; Shares Fall
Genprex (GNPX) said Tuesday it launched a stock offering to raise $6.5 million. The offering of 1.54 million common shares and accompanying warrants was priced at $4.215 a share, the company said. The
Genprex Falls 10% After Pricing Its Offering to Raise $6.5M
Genprex Announces $6.5M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex Announces $6.5M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AUSTIN, Texas — (March 19, 2024) — Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients wi
Express News | Genprex Receives Notice Of Patent Grant For Korean Patent Claiming Reqorsa Immunogene Therapy With PD-1 And PD-L1 Antibodies To Treat Cancers
Express News | Genprex Collaborators To Present Preclinical Data On Use Of Reqorsa And On NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System For Lung Cancers At 2024 AACR Annual Meeting
Genprex Expands Nonclinical Programs Into New Therapeutic Indications With Research Collaborators
Reqorsa Therapy May Be Potential Treatment for ALK-Positive Lung Cancer Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 Ame
Genprex Launches Phase 2a Reqorsa Trial Expansion
Genprex to Present at Upcoming BIO CEO & Investor Conference
Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas — (Feb. 6, 2024) — Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-sta
Genprex Shares Climb After First Patient Dosing in Reqorsa-Tagrisso Trial
By Dean Seal Genprex shares jumped after the first non-small cell lung cancer patient was enrolled and dosed in a Phase 2 study of its drug Reqorsa in combination with AstraZeneca's Tagrisso. The st
CTLT, BTAI and CAMP Are Among Pre Market Gainers
No Data